explore -WSS

explore

author：hotspot 2025-09-06 06:17:00 - browse：41

Susan Tousi is leaving Illumina to become CEO of cancer liquid-biopsy startup Delfi. Nasdaq

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June.

Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference, while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs. Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and build on the initial launch of its lung cancer screening test last fall, the latest example of growing interest in the vast and increasingly competitive liquid biopsy market.

Illumina’s own ambitions to enter this space recently came undone after a prolonged battle with U.S. and European regulators finally pushed the company to announce last month that it would divest Grail, which it had acquired for $8 billion two years earlier. Bas Verhoef, Illumina’s head of region for Europe, will serve as interim chief commercial officer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Food makers to regulators: Ultra

hotspot

WSS

Wildfire smoke exposes gaps in outdoor worker protections

Long Covid needs a new name — and a new frame

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Cancer drug shortages should be causing more outrage

State Dept. review finds Biden bears some blame for Afghanistan failures

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

leisure time

explore

hotspot

Medicare details structure of new drug price negotiation program

FDA proposes changes to key medical devices approval pathway

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Regeneron agrees to White House price limits on anti

Novavax promises a turnaround & Lilly roils the obesity market

Hollywood unions extend contract negotiations for actors

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare proposal to cover medical devices draws a mixed reaction

How to save PrEP access — and even expand it

Long Covid needs a new name — and a new frame

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Tori Bowie and the unacceptable rates of Black maternal death

Acelyrin, a rare IPO success, stumbles in its first big test

Tori Bowie and the unacceptable rates of Black maternal death

Psychedelics group wrestles with new pharma identity

United colonoscopy coverage change 'may cost lives,' doctors say

Wikipedia

hotspot

entertainment

leisure time